SenesTech, Inc. (SNES) Stock Price & Analysis
SenesTech, Inc. (SNES) closed at USD 0.84 on Friday, October 23, 2026, up 5.13% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.84; the Oct 23, 2026 session ranged USD 0.77–0.86 on volume of 254,623 shares. Market capitalization is —, with a 52-week range of USD 0.55–3.85 (NCM). Source: Nexqual, retrieved October 24, 2026 at 11:50 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SNES.md
Key facts (SNES)
- Last four reported quarters (through Jun 30, 2026): revenue $2.4M, net income -$7.0M (-294.7% margin), free cash flow -$6.7M (SEC filings).
- Total return with dividends: 1Y -77.7% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
- Next earnings: 2026-11-09, EPS estimate USD -0.33, revenue estimate $797K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SNES)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $600K | $1.0M | $1.2M | $1.9M | $2.2M | $2.4M |
| Gross profit | $244K | $464K | $539K | $1.0M | $1.4M | — |
| Operating income | -$8.9M | -$9.7M | -$7.7M | -$6.2M | -$6.5M | -$7.2M |
| Net income | -$8.3M | -$9.7M | -$7.7M | -$6.2M | -$6.4M | -$7.0M |
| EPS (diluted) | -$1772.40 | -$1480.80 | -$115.10 | -$8.86 | -$1.95 | — |
| Free cash flow | -$7.9M | -$8.8M | -$7.7M | -$6.1M | -$5.9M | -$6.7M |
| Gross margin | 40.7% | 45.5% | 45.2% | 54.1% | 62.5% | — |
| Operating margin | -1489.0% | -949.4% | -648.1% | -336.5% | -292.9% | -303.7% |
| Net margin | -1378.0% | -951.4% | -646.3% | -333.0% | -287.4% | -294.7% |
| Revenue growth | +112.8% | +69.8% | +17.1% | +55.7% | +19.6% | — |
| Cash + short-term investments | $9.3M | $4.8M | $5.4M | $1.3M | $8.6M | — |
| Total debt | $32K | $0K | $156K | $206K | $145K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SNES)
Total return (dividends reinvested) (SNES)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -77.7% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -77.8% | -81.2% |
| Volatility (annualized) | 85.0% | 97.6% |
| Max drawdown | -83.3% (Oct 2025→Oct 2026) | -100.0% (Nov 2021→Oct 2026) |
SNES customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (45%, 2%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.
SNES company outlook (results filed Oct 15, 2026)
- “These include statements regarding the Company's expected third quarter 2026 revenue, anticipated momentum in e-commerce and increasing traction in B2B, expected progress across the Company's commercial model, and anticipated continued, improved metrics going forward.”
Quoted word-for-word from the SEC 8-K results press release.
SNES analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.33 | $-0.35 | -7.1% | $797,000 | 2 |
| Next quarter (ends Dec 2026) | $-0.33 | $-0.34 | -4.4% | $868,000 | 2 |
| Current fiscal year (ends Dec 2026) | $-1.39 | $-1.36 | +1.8% | $2.9M | 2 |
| Next fiscal year (ends Dec 2027) | $-1.10 | $-1.30 | -15.0% | $4.5M | 2 |
Key Statistics (as of October 24, 2026 at 11:50 UTC)
| Price | USD 0.84 |
|---|---|
| Change | ▲ 5.13% (up) |
| Previous Close | USD 0.84 |
| Open | USD 0.84 |
| Day Range | USD 0.77 – 0.86 |
| 52-Week Range | USD 0.55 – 3.85 |
| Volume | 254,623 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SNES)
Nexqual's technical model rates SNES "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 24, 2026 at 11:50 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 58.41 (neutral) |
| vs SMA50 | Below (USD 0.89) |
| MACD | -0.03 (negative) |
Earnings (SNES)
| Next Earnings Date | 2026-11-09 |
|---|---|
| Revenue Estimate | $797,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.35 vs est -0.37 ▲ beat |
| 2025-12-31 | USD -0.35 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.28 vs est -0.35 ▲ beat |
Source: Nexqual, October 24, 2026 at 11:50 UTC.
Financials & Fundamentals (SNES)
| Total Revenue | $2.37M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.20% |
| Gross Margin | +66.17% |
| Operating Margin | -241.82% |
| Profit Margin | -294.73% |
| ROE | -107.41% |
| Debt / Equity | 0.43 |
| Current Ratio | 6.78 |
| Total Cash | $5.08M |
| Total Debt | $2.58M |
Source: Nexqual, October 24, 2026 at 11:50 UTC.
Ownership (SNES)
| Insider Ownership | +4.26% |
|---|---|
| Institutional Ownership | +47.39% |
| Shares Outstanding | 5.30M |
| Float | 4.11M |
| Short % of Float | +0.59% |
Source: Nexqual, October 24, 2026 at 11:50 UTC.
From SenesTech, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- While our proprietary technology is predominantly effective on rats, it may be applied to mice and other mammalian species.
- We seek to protect our proprietary data and trade secrets with attention to data exchanges among employees, consultants, collaborators and research and trade partners.
- Once incorporated, the entire product undergoes a proprietary process in order to stabilize the final formulation.
- We have developed and are commercializing products for managing animal pest populations through fertility control and population management strategies.
Legal & Regulatory Risks (Item 1A, quoted)
- Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, if approved, and could significantly harm our business, results of operations and prospects.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPCB | SuperCom, Ltd. | USD 9.31 | ▲ 2.31% |
| TENX | Tenax Therapeutics, Inc. | USD 1.72 | ▼ 2.27% |
| XMAX | XMAX, Inc. | USD 8.66 | ▼ 1.03% |
| PWCM | PowerCompute, Inc. | USD 0.61 | ▲ 0.94% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 3.48% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 11:50 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt